News & events

News & events
<picture><source type="image/webp" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/18e05/Image.webp 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/81bef/Image.webp 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/2d0b8/Image.webp 2960w" sizes="(min-width: 2960px) 2960px, 100vw"/><img data-gatsby-image-ssr="" data-main-image="" style="opacity:0" sizes="(min-width: 2960px) 2960px, 100vw" decoding="async" loading="lazy" src="/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg" srcSet="/static/bd6d2c42e99d69343f6fd727c3137fdd/bbd3f/Image.jpg 740w,/static/bd6d2c42e99d69343f6fd727c3137fdd/087e6/Image.jpg 1480w,/static/bd6d2c42e99d69343f6fd727c3137fdd/c9eb6/Image.jpg 2960w" alt="&lt;p&gt;Image of a middle aged man dressed in a blazer, clapping his hands while smiling.&lt;/p&gt;
"/></picture>

News
21 September 2023Latest
Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will present novel clinical and preclinical data on the mode of action of its...
Learn more
8 September 2023
Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that it has received Fast Track Designation from the U.S. Food...
Learn more
6 September 2023
Mendus Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference in September
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company will present a company presentation and...
Learn more
4 September 2023
Mendus to participate in multiple investor and industry conferences in September
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and...
Learn more
31 August 2023
Change in number of shares and votes in Mendus AB (publ)
As previously announced Mendus AB (publ) (“Mendus”) has carried out a capital raise whereby 472,953,859 new shares were issued in a rights issue and 187,500,000 new shares were issued in a directed...
Learn more
29 August 2023
Mendus AB (publ) Interim Report January – June 2023
“In the second quarter of 2023, Mendus’ main objectives were focused on driving the evolution of our pipeline and securing the related financing. The progress made in the previous quarters, including...
Learn more
16 August 2023
Mendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies
INTRATUMORAL PRIMING BOOSTED THE THERAPEUTIC EFFICACY OF ANTI-4-1BB ANTIBODY TREATMENT AND RESULTED IN A MORE TREATMENT-SUPPORTIVE TME    Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical...
Learn more

Events
27 September 2023
Upcoming
Nordic Conference and Opening Ceremony of NorthX Innovation HubMendus Board member Hans Preusting will participate at the event.
Learn more
September 2023Previous
CICON23 – International Cancer Immunotherapy Conference
Mendus to present preclinical and clinical data on the mode of action of its lead clinical program vididencel.
Learn more
September 2023Previous
Pareto Securities’ Annual Healthcare Conference
Mendus CEO Erik Manting and CFO Lotta Ferm will participate and present a Company Update at the conference.
Learn more
September 2023Previous
H.C. Wainwright 25th Annual Global Investment Conference
Mendus CEO Erik Manting will participate and present a Company Update at the conference.
Learn more

.FullWidthImage-module--bg-image-mobile--ba5fc.FullWidthImage-module--hide-in-mobile--9cd89.gbi-1002417752-ppMrhyZ4otGQK7JYz26eC4:before { opacity: 1; background-image: url('/static/755e562542c233156a7bec1f19e2a86b/afb86/new-events-mobile.png'); }

InvestorsAt Mendus, we share a strong commitment to improve the lives of people with cancer.
Investors

News

Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23

Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)

Mendus Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference in September

Mendus to participate in multiple investor and industry conferences in September

Change in number of shares and votes in Mendus AB (publ)

Mendus AB (publ) Interim Report January – June 2023

Mendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies

Events

Nordic Conference and Opening Ceremony of NorthX Innovation Hub

CICON23 – International Cancer Immunotherapy Conference

Pareto Securities’ Annual Healthcare Conference

H.C. Wainwright 25th Annual Global Investment Conference

Investors

Keep up to date